The company is a non-banking financial institution that provides secured loans to small and medium-sized businesses, healthcare providers, and renewable energy projects, while also managing a portfolio of equity investments.
The company lacks a durable competitive advantage as its lending operations are in their infancy and its historical returns have been driven by a volatile equity portfolio rather than proprietary cost or scale advantages. ROCE and ROE are currently in the mid-single digits, which is below the typical cost of capital for the sector.
Management has shifted focus from passive equity investing to active lending, funded by a significant rights issue in 2025. While the pivot targets high-growth sectors like healthcare and solar, the track record is too short to judge if these reinvestments will generate returns above the cost of equity.
The pivot from passive equity holdings to active lending proved disastrous as the company's lack of underwriting expertise led to a surge in non-performing assets. The capital raised in 2025 was incinerated by lending to related-party entities in the healthcare and education sectors, which failed to generate the promised cash flows. As the volatile equity portfolio continued to suffer fair value losses, the negative interest coverage and poor cash conversion finally triggered a liquidity crisis, leaving shareholders with a hollowed-out shell of a financial institution.
RichFakir rates Crescentis Capital Ltd's business quality as poor — 29/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Crescentis Capital Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Crescentis Capital Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Crescentis Capital Ltd's fair value is about ₹7 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →